Keratoconus is a progressive corneal ectasia that can lead to significant visual impairment and decreased quality of life. The introduction of corneal cross-linking (CXL) with riboflavin and ultraviolet-A (UVA) light has revolutionized the treatment of keratoconus by increasing corneal rigidity and arresting disease progression. The epithelium-off protocol, which induces heightened post-surgical discomfort, is the prevailing approach. Despite the success of CXL, postoperative pain is a common side effect that can negatively impact patients' quality of life and impede recovery. Pain management after CXL is essential for optimizing patient outcomes and satisfaction. Systemic painkillers, though not researched enough, may potentially aid in healing and recovery, minimizing complications and discomfort for the patient. In this study we will provide evidence-based recommendations for clinicians to optimize pain control after CXL in collaboration with pain specialists.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Enrollment
51
Gabapentin 200 mg twice a day, starting from the night prior to the procedure and continue 48 hours after
Targin 5 mg twice a day after the procedure for 48 hours
Nurofen (NSAID) 200 mg twice a day after the procedure for 48 hours
Paracetamol 500 mg every 4 hours during waking hours after the procedure for 48 hours
Shamir Medical Center (Assaf Harofeh)
Be’er Ya‘aqov, Israel
Pain questionnaires
Time frame: The questionnaire will be asked 2, 6, 24 48 and 72 hours after surgery.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.